08:52 AM EDT, 03/13/2024 (MT Newswires) -- Catalyst Pharmaceuticals ( CPRX ) said Wednesday that it has commercially launched Agamree to treat Duchenne Muscular Dystrophy in patients aged two years and older.

The US Food and Drug Administration approved Agamree in late October. It is now available by prescription in the US.

The FDA's approval was based on data from a phase 2b study, and supplemented with safety information from three open-label studies.